Lukas C - Search Results

1

Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.

Pontillo G, Prados F, Colman J, Kanber B, Abdel-Mannan O, Al-Araji S, Bellenberg B, Bianchi A, Bisecco A, Brownlee WJ, Brunetti A, Cagol A, Calabrese M, Castellaro M, Christensen R, Cocozza S, Colato E, Collorone S, Cortese R, De Stefano N, Enzinger C, Filippi M, Foster MA, Gallo A, Gasperini C, Gonzalez-Escamilla G, Granziera C, Groppa S, Hacohen Y, Harbo HFF, He A, Hogestol EA, Kuhle J, Llufriu S, Lukas C, Martinez-Heras E, Messina S, Moccia M, Mohamud S, Nistri R, Nygaard GO, Palace J, Petracca M, Pinter D, Rocca MA, Rovira A, Ruggieri S, Sastre-Garriga J, Strijbis EM, Toosy AT, Uher T, Valsasina P, Vaneckova M, Vrenken H, Wingrove J, Yam C, Schoonheim MM, Ciccarelli O, Cole JH, Barkhof F; MAGNIMS study group.. Pontillo G, et al. Among authors: lukas c. Neurology. 2024 Nov 26;103(10):e209976. doi: 10.1212/WNL.0000000000209976. Epub 2024 Nov 4. Neurology. 2024. PMID: 39496109 Free PMC article.

2

Sensitivity and reproducibility of a new fast 3D segmentation technique for clinical MR-based brain volumetry in multiple sclerosis.

Lukas C, Hahn HK, Bellenberg B, Rexilius J, Schmid G, Schimrigk SK, Przuntek H, Köster O, Peitgen HO. Lukas C, et al. Neuroradiology. 2004 Nov;46(11):906-15. doi: 10.1007/s00234-004-1282-3. Epub 2004 Nov 5. Neuroradiology. 2004. PMID: 15536555

3

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, Przuntek H. Schimrigk S, et al. Among authors: lukas c. Eur J Neurol. 2006 Jun;13(6):604-10. doi: 10.1111/j.1468-1331.2006.01292.x. Eur J Neurol. 2006. PMID: 16796584 Clinical Trial.

4

Dissociation of grey and white matter reduction in spinocerebellar ataxia type 3 and 6: a voxel-based morphometry study.

Lukas C, Schöls L, Bellenberg B, Rüb U, Przuntek H, Schmid G, Köster O, Suchan B. Lukas C, et al. Neurosci Lett. 2006 Nov 20;408(3):230-5. doi: 10.1016/j.neulet.2006.09.007. Epub 2006 Sep 26. Neurosci Lett. 2006. PMID: 17005321

5

Spinal cord atrophy in spinocerebellar ataxia type 3 and 6 : impact on clinical disability.

Lukas C, Hahn HK, Bellenberg B, Hellwig K, Globas C, Schimrigk SK, Köster O, Schöls L. Lukas C, et al. J Neurol. 2008 Aug;255(8):1244-9. doi: 10.1007/s00415-008-0907-6. Epub 2008 Jun 5. J Neurol. 2008. PMID: 18506570

6

HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis.

Sombekke MH, Lukas C, Crusius JB, Tejedor D, Killestein J, Arteta D, Martínez A, Uitdehaag BM, Knol DL, Peña AS, Geurts JJ, De Jager PL, Barkhof F, Vrenken H, Polman CH. Sombekke MH, et al. Among authors: lukas c. Arch Neurol. 2009 Dec;66(12):1531-6. doi: 10.1001/archneurol.2009.278. Arch Neurol. 2009. PMID: 20008659

7

Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla.

Simon B, Schmidt S, Lukas C, Gieseke J, Träber F, Knol DL, Willinek WA, Geurts JJ, Schild HH, Barkhof F, Wattjes MP. Simon B, et al. Among authors: lukas c. Eur Radiol. 2010 Jul;20(7):1675-83. doi: 10.1007/s00330-009-1705-y. Epub 2010 Jan 22. Eur Radiol. 2010. PMID: 20094887 Free PMC article. Clinical Trial.

8

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.

Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R. Schröder A, et al. Among authors: lukas c. Arch Neurol. 2010 Nov;67(11):1391-4. doi: 10.1001/archneurol.2010.157. Epub 2010 Jul 12. Arch Neurol. 2010. PMID: 20625069

9

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis.

Lukas C, Minneboo A, de Groot V, Moraal B, Knol DL, Polman CH, Barkhof F, Vrenken H. Lukas C, et al. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1351-6. doi: 10.1136/jnnp.2009.199968. Epub 2010 Sep 8. J Neurol Neurosurg Psychiatry. 2010. PMID: 20826873

10

Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy.

Lukas C, Bellenberg B, Hahn HK, Rexilius J, Drescher R, Hellwig K, Köster O, Schimrigk S. Lukas C, et al. Ther Adv Neurol Disord. 2009 Nov;2(6):42-9. doi: 10.1177/1756285609343480. Ther Adv Neurol Disord. 2009. PMID: 21180629 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

360 results

Search Page

Filters